New Weight-Loss drug tested in kidney patients

NCT ID NCT07559240

Not yet recruiting Knowledge-focused Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study will test a single dose of the experimental drug HDM1005 in 30 overweight or obese adults, some with moderate or severe kidney disease and some with healthy kidneys. The goal is to see how kidney function affects the drug's levels in the body and to check for safety issues. This is a Phase 1 trial, meaning it's one of the first steps in human testing, so it's focused on safety and drug processing rather than weight loss itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HDM1005 injection
What this could lead to: If successful, this study could help determine safe dosing of HDM1005 for people with kidney problems, potentially leading to a weight management option for this group.
What could go wrong: This is a very early Phase 1 study with only 30 participants, so results may not apply broadly. The drug may not work as expected or could have side effects, especially in those with kidney impairment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESE OVERWEIGHT

Contacts and locations

Locations

Peking University Third Hospital

Beijing, 100191, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.